Who is sponsoring NCT04509648?

NCT04509648 is sponsored by Ruijin Hospital.

What drugs are being tested in NCT04509648?

Interventions in NCT04509648: External Beam radiotherapy using IMRT technique.

What condition does NCT04509648 study?

NCT04509648 studies Breast Cancer.

Is NCT04509648 still recruiting?

NCT04509648 is currently active, enrolled. Last updated 21 January 2026.

Last reviewed 2026-01-21 · How we verify

NCT04509648: ARROW

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant Regional Nodal Radiation Therapy for One Week in Breast Cancer

Active, enrolled NA Last updated 21 January 2026

What this trial tests

NA trial testing External Beam radiotherapy using IMRT technique in Breast Cancer in 197 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

21 January 2021

Primary endpoint
30 August 2026

30 December 2030

Quick facts

Lead sponsor	Ruijin Hospital
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	197
Start date	21 January 2021
Primary completion	30 August 2026
Estimated completion	30 December 2030
Sites	1 location across China

Drugs / interventions tested

External Beam radiotherapy using IMRT technique

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Ruijin Hospital

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to investigate the toxicities and efficacy of super hypofractionated regional nodal radiotherapy (RNI) for one week in breast cancer patients treated with mastectomy or breast conserving surgery. Super hypofractionated radiotherapy will be delivered to chest wall or whole breast and regional lymph regions (including supraclavicular/infraclavicular region, internal mammary nodes, and any part of the axillary bed at risk). Eligible breast cancer patients will be followed for at least 5 years to evaluate the acute and late radiation-induced toxicities, locoregional recurrence, over survival, distant metastasis, and quality of life.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial.
Xie J, Xu F, Zhao Y, Cai G, et al · · 2022 · cited 9× · PMID 36581983 · DOI 10.1136/bmjopen-2022-062034
Ultra-hypofractionated one-week locoregional radiotherapy for patients with early breast cancer: Acute toxicity results.
Ratosa I, Montero A, Ciervide R, Alvarez B, et al · · 2024 · cited 6× · PMID 38516338 · DOI 10.1016/j.ctro.2024.100764
Evaluation of complexity and deliverability of IMRT treatment plans for breast cancer.
Duan L, Qi W, Chen Y, Cao L, et al · · 2023 · cited 6× · PMID 38052915 · DOI 10.1038/s41598-023-48331-x
One-week regimen for postoperative regional irradiation in breast cancer: the ARROW trial protocol.
Xie J, Zheng S, Qi WX, Gan L, et al · · 2025 · PMID 40379319 · DOI 10.1136/bmjopen-2024-096677

Verify or expand the search:

Other trials of External Beam radiotherapy using IMRT technique

Trials testing the same drug.

NCT04926766 — Super Hypofractionated Irradiation for Whole Breast Treatment · NA · active not recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Ruijin Hospital trials

Trials by the same sponsor.

NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04509648 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
Last refreshed: 21 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04509648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing